Correlation Between Viracta Therapeutics and EnGene Holdings

Can any of the company-specific risk be diversified away by investing in both Viracta Therapeutics and EnGene Holdings at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Viracta Therapeutics and EnGene Holdings into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Viracta Therapeutics and enGene Holdings Common, you can compare the effects of market volatilities on Viracta Therapeutics and EnGene Holdings and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Viracta Therapeutics with a short position of EnGene Holdings. Check out your portfolio center. Please also check ongoing floating volatility patterns of Viracta Therapeutics and EnGene Holdings.

Diversification Opportunities for Viracta Therapeutics and EnGene Holdings

-0.32

Correlation Coefficient

Viracta Therapeutics  EnGene Holdings

Very good diversification

The 3 months correlation between Viracta and EnGene is -0.32. Overlapping area represents the amount of risk that can be diversified away by holding Viracta Therapeutics and enGene Holdings Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on enGene Holdings Common and Viracta Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Viracta Therapeutics are associated (or correlated) with EnGene Holdings. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of enGene Holdings Common has no effect on the direction of Viracta Therapeutics i.e., Viracta Therapeutics and EnGene Holdings go up and down completely randomly.

Pair Corralation between Viracta Therapeutics and EnGene Holdings

Given the investment horizon of 90 days Viracta Therapeutics is expected to under-perform the EnGene Holdings. But the stock apears to be less risky and, when comparing its historical volatility, Viracta Therapeutics is 1.04 times less risky than EnGene Holdings. The stock trades about -0.07 of its potential returns per unit of risk. The enGene Holdings Common is currently generating about 0.06 of returns per unit of risk over similar time horizon. If you would invest  665.00  in enGene Holdings Common on September 12, 2024 and sell it today you would earn a total of  86.00  from holding enGene Holdings Common or generate 12.93% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	98.46%
Values	Daily Returns

Viracta Therapeutics  vs.  enGene Holdings Common

Viracta Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Viracta Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

enGene Holdings Common

Risk-Adjusted Performance

4 of 100

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in enGene Holdings Common are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of very weak technical and fundamental indicators, EnGene Holdings displayed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Viracta Therapeutics and EnGene Holdings

The main advantage of trading using opposite Viracta Therapeutics and EnGene Holdings positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Viracta Therapeutics position performs unexpectedly, EnGene Holdings can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in EnGene Holdings will offset losses from the drop in EnGene Holdings' long position.

The idea behind Viracta Therapeutics and enGene Holdings Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.